Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPREDICT transcriptomic-guided neoadjuvant chemotherapy for borderline resectable pancreatic adenocarcinoma
2024-519753-11-00Phase 2Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, gemcitabine, fluorouracil, irinotecan, oxaliplatin and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: 1-year event-free survival. Planned start Jul 2026; status: authorised.
02
Drugs
paclitaxelgemcitabinefluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-519753-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519753-11-00.